# BeiGene's First-in-Class AKT1 Selective Inhibitor TER-2013 IND Application Accepted by China's NMPA

> China's National Medical Products Administration accepted the clinical trial application for TER-2013 tablets on November 18, 2026. TER-2013 is described as the first selective AKT1 inhibitor, developed by Terremoto Biosciences and partnered with BeOne. The drug has been in a global Phase 1/2 trial since September 2025.

- Date: 2026-11-21 · published 2026-11-21T06:17:02.477Z
- Category: market · region China · magnitude low
- Page: https://feedsoft.ai/events/112062-beigene-s-first-in-class-akt1-selective-inhibitor-ter-2013-ind-application
- Commodities: [Lysine](https://feedsoft.ai/c/LYSINE.md)

## Why it matters

This is a pharmaceutical regulatory milestone with no link to feed grain, protein or additive supply, demand or prices, so it has no price implication for feed buyers.

## Sources

- vcbeathealth.com: https://www.vcbeathealth.com/article/65080

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.
